A study of human epidermal growth factor receptor 2 overexpression by immunohistochemistry in patients with gastric adenocarcinoma

Authors

  • Rafid A. Abood Basra College of Medicine; Basra Oncology and Hematology Center https://orcid.org/0000-0002-8615-4099
  • Saad Alomar Basra College of Medicine; Depatment of Pathology, Al Sadar Teaching Hospital https://orcid.org/0000-0002-6912-3872
  • Sawsan S. Alharoon Basra College of Medicine; Depatment of Pathology, Al Sadar Teaching Hospital

DOI:

https://doi.org/10.4081/jphia.2023.2721

Keywords:

Gastric cancer, adenocarcinoma, HER2, overactivity, Iraq, clinicopathological features, prevalence

Abstract

Gastric cancer is one of the leading causes of cancer‑related deaths across the world and in the Middle East. Human epidermal growth factor receptor 2 (HER2) overexpression has been observed in gastric cancers. Trastuzumab, a recombinant monoclonal antibody targeting HER2 protein, is being used for treatment of metastatic gastric cancer. To study the frequency and association of HER2 overexpression with age, gender, histopathological subtype and grade of differentiation in patients with gastric adenocarcinoma from Basra, Iraq. This cross‑sectional single‑center study collected demographic (age, gender), histopathological (histological subtype, grade of differentiation) and immunohistochemical (HER2 overexpression status) data from 100 consenting adult patients (male: 56) with histopathologically confirmed gastric adenocarcinoma from samples obtained through endoscopy or surgery. HER2 overexpression (ToGA score 3+) was observed in 6/100 (6%) of patients, with another 6 showing ‘equivocal’ HER2 expression (2+). Out of 20 patients with moderately differentiated gastric cancer, 4 (20%) showed HER2 overexpression (P=0.008). Other factors considered (age, gender, histological subtype) did not show statistically significant correlation with HER2 overexpression. More females showed HER2 overexpression than males (4 vs. 2), and more patients with intestinal type gastric cancer showed HER2 overexpression than diffuse gastric cancer (5 vs. 1), but the difference was not statistically significant in both variables. HER2 overexpression was 6% in this population; statistically significant correlation was found with histological grade. Statistically non‑significant correlations were observed between HER2 overexpression and gender, age, and histological subtype.

Download data is not yet available.

References

Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018 Feb 7;10:239-248. DOI: https://doi.org/10.2147/CMAR.S149619

AL-Janabi AAHS, Naseer ZH, Hamody TA. Epidemiological study of cancers in Iraq-Karbala from 2008 to 2015. Int J Med Res Health Sci. 2017;6(1):79-86.

Avital I, Stojadinovic A, Pisters PWT, Kelsen DP, Willett CG. Cancer of the Stomach. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, PA: Wolters Kluwer; 2015. 613-42.

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across fi ve continents: defi ning priorities to reduce cancer disparities in diff erent geographic regions of the world. J Clin Oncol 2006; 24: 2137–50. DOI: https://doi.org/10.1200/JCO.2005.05.2308

Cunningham D, Allum WH, Stenning SP, et al, for the MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355: 11–20. DOI: https://doi.org/10.1056/NEJMoa055531

Kuo CY, Chao Y, Li CP. Update on treatment of gastric cancer. J Chin Med Assoc. 2014 Jul;77(7):345-53. DOI: https://doi.org/10.1016/j.jcma.2014.04.006

Phan DAT, Nguyen VT, Hua TNH, Ngo QD, Doan TPT, Nguyen ST, Thai AT, Nguyen VT. HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient. J Pathol Transl Med. 2017 Jul;51(4):396-402. DOI: https://doi.org/10.4132/jptm.2017.04.24

Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014 Jan;17(1):1-12. DOI: https://doi.org/10.1007/s10120-013-0252-z

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28; 376(9742):687-97. DOI: https://doi.org/10.1016/S0140-6736(10)61121-X

Kelly CM, Janjigian YY. The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. J Gastrointest Oncol. 2016 Oct;7(5):750-762. DOI: https://doi.org/10.21037/jgo.2016.06.10

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52(7):797–805. DOI: https://doi.org/10.1111/j.1365-2559.2008.03028.x

Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, et al: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010, 457(3):299–307. DOI: https://doi.org/10.1007/s00428-010-0952-2

Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016 May 21;22(19):4619-25. DOI: https://doi.org/10.3748/wjg.v22.i19.4619

Al Azow NS. HER2/neu overexpression in gastric cancer. The Iraqi Postgraduate Medical Journal 2014;13(2):268-72.

Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013 May 9;8:76. DOI: https://doi.org/10.1186/1746-1596-8-76

Shabbir A, Qureshi MA, Khalid AB, Mirza T, Shaikh A, Hasan SM. Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population. Saudi J Gastroenterol. 2018 Sep-Oct;24(5):289-293. DOI: https://doi.org/10.4103/sjg.SJG_23_18

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011;135(11):1460–1465. DOI: https://doi.org/10.5858/arpa.2010-0541-OA

Nadaf AS, Rani H, Dinesh US. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India. Asian Pac J Cancer Prev. 2018 May 26;19(5):1381-1385.

Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011;18(10):2833–40. DOI: https://doi.org/10.1245/s10434-011-1695-2

Downloads

Published

03-08-2023

How to Cite

Abood, R. A., Alomar, S., & Alharoon, S. S. (2023). A study of human epidermal growth factor receptor 2 overexpression by immunohistochemistry in patients with gastric adenocarcinoma. Journal of Public Health in Africa, 14(9). https://doi.org/10.4081/jphia.2023.2721

Issue

Section

Original Articles